Emilie Desodt - Genfit Executive Resources
| GNFT Stock | USD 4.26 0.06 1.43% |
Executive
Emilie Desodt is Executive Resources of Genfit
| Age | 41 |
| Address | Parc EurasantE, Loos, France, 59120 |
| Phone | 33 3 20 16 40 00 |
| Web | https://www.genfit.com |
Genfit Management Efficiency
The company has return on total asset (ROA) of 0.0651 % which means that it generated a profit of $0.0651 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2591 %, meaning that it created $0.2591 on every $100 dollars invested by stockholders. Genfit's management efficiency ratios could be used to measure how well Genfit manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2024. Return On Capital Employed is likely to drop to -0.21 in 2024. Total Current Liabilities is likely to drop to about 24.2 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 135.4 M in 2024Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jennifer Huber | AN2 Therapeutics | N/A | |
| MBA JD | Harmony Biosciences Holdings | 49 | |
| Anne DVM | Molecular Partners AG | N/A | |
| Christian JD | Harmony Biosciences Holdings | N/A | |
| Michael Covarrubias | Rezolute | N/A | |
| Nicole Esq | HCW Biologics | N/A | |
| Yung MD | Keros Therapeutics | 48 | |
| Yan MBA | Adagene | 49 | |
| MD MBA | Eliem Therapeutics | 50 | |
| Dr MBA | Acrivon Therapeutics, Common | N/A | |
| Robin Wagner | Keros Therapeutics | N/A | |
| Cate McCanless | Harmony Biosciences Holdings | N/A | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| CPA CFA | Janux Therapeutics | 48 | |
| Pamela Trail | Molecular Partners AG | 68 | |
| Daniel George | Anebulo Pharmaceuticals | 54 | |
| MaryAlice JD | Acrivon Therapeutics, Common | 50 | |
| Ling Zhou | Adagene | N/A | |
| MS MD | Harmony Biosciences Holdings | N/A | |
| Christian Ulrich | Harmony Biosciences Holdings | N/A | |
| Marinus Verwijs | Aerovate Therapeutics | 48 | |
Management Performance
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.0651 |
Genfit Leadership Team
Elected by the shareholders, the Genfit's board of directors comprises two types of representatives: Genfit inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genfit. The board's role is to monitor Genfit's management team and ensure that shareholders' interests are well served. Genfit's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genfit's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stefanie JD, Chief Affairs | ||
| Pascal Caisey, Chief Officer | ||
| Dean Hum, COO, Chief Scientific Officer, Member of the Management Board | ||
| Thomas Baetz, Chief Officer | ||
| Pr Staels, CoFounder Board | ||
| JeanChristophe Marcoux, Chief Officer | ||
| Meriam Kabbaj, Chief Officer | ||
| Pascal Prigent, Chief Officer | ||
| Laurent Lannoo, Corporate Affairs | ||
| JeanFrancois Mouney, Chairman of the Management Board, CEO | ||
| John Brozek, Executive Technology | ||
| Stefanie Magner, Chief Affairs | ||
| Emilie Desodt, Executive Resources |
Genfit Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genfit a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.0651 | ||||
| Profit Margin | 0.28 % | ||||
| Operating Margin | 0.51 % | ||||
| Current Valuation | 218.56 M | ||||
| Shares Outstanding | 49.91 M | ||||
| Shares Owned By Institutions | 0.25 % | ||||
| Number Of Shares Shorted | 63.36 K | ||||
| Price To Earning | 4.72 X | ||||
| Price To Book | 2.06 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Genfit Stock Analysis
When running Genfit's price analysis, check to measure Genfit's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genfit is operating at the current time. Most of Genfit's value examination focuses on studying past and present price action to predict the probability of Genfit's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genfit's price. Additionally, you may evaluate how the addition of Genfit to your portfolios can decrease your overall portfolio volatility.